Combinatorial therapies simultaneously targeting multiple pathways such as PI3K/MAPK, growth factors that may confer resistance, and immunotherapies should be explored in the setting of treating naïve c-KIT-mutant melanoma and patients with acquired resistance to c-KIT inhibitors. This evidence concerns the gene PIK3CA and melanoma.